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ILLUSTRATIVE CASE
A 52-year-old man presents to your offi ce 
for follow-up 2 days after he was seen in 
the ED and diagnosed with a distal ureter-
al calculus, his fi rst. His pain is reasonably 
well controlled, but he has not yet passed 
the stone. Is there anything you can do to 
help him pass the stone? 
Yes. Patients who are candidates for observation should be offered a tri-al of “medical expulsive therapy” 
using an α−antagonist or a calcium chan-
nel blocker. Until now, medical therapy for 
kidney stones consisted of pain relief only.
The ordeal of a fi rst stone is all too 
common—the lifetime prevalence of 
kidney stones is 5.2%—and the prob-
ability of recurrence is about 50%.2,3
NHANES data show increasing preva-
lence between the periods 1976-1980 
and 1988-1996.3 One fi fth to one 
third of kidney stones require surgical 
intervention.4 In a cohort of 245 pa-
tients presenting to an ED in Canada, 
50 (20%) required further procedures, 
including lithotripsy. Stones ≥ 6 mm in 
size were much less likely to pass (OR 
= 10.7, 95% CI 4.6-24.8).5 The burden 
on the healthcare system is signifi cant; 
there are approximately 2 million out-
patient visits annually for this problem, 
and diagnosis and treatment costs about 
$2 billion annually.6
❚ Watch and wait
The standard approach is a period of 
watchful waiting and pain control, with 
urgent urological referral for patients with 
evidence of upper urinary tract infection, 
high grade obstruction, inadequate pain 
or nausea control, or insuffi cient renal re-
serve.2,4 Most patients treated with watch-
ful waiting pass their stone within 4 weeks. 
Any stones that don’t pass within 8 weeks 
are unlikely to pass spontaneously.2,7
❚  Medical therapy has been 
proposed for decades
Medications that relax ureteral smooth 
muscle to help pass ureteral stones have 
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more ureteral stones
Evidence supports use of tamsulosin, nifedipine
Prescribe tamsulosin (typically 
0.4 mg daily) or nifedipine (typ-
ically 30 mg daily) for patients 
with lower ureteral calculi, to 
speed stone passage and to 
avoid surgical intervention. 
Strength of recommendation 
A: Meta-analysis of randomized controlled trials
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PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and ﬁ ndings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
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Patients who are 
candidates for 
observation should 
be offered a trial of 
“medical expulsive 
therapy” using an 
α-antagonist or 
nifedipine
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been proposed for decades.8 Prior to 
2000, however, only 1 randomized con-
trolled trial (RCT) of medical therapy for 
ureteral stones had been published.9 A 
subsequent meta-analysis found 9 stud-
ies and showed that medical therapy did 
increase the chances that a stone would 
pass.10 The Singh meta-analysis found 13 
subsequently published studies and near-
ly tripled the number of patients evalu-
ated.
STUDY SUMMARY
❚  A well-done 
meta-analysis
This meta-analysis is based on 16 studies 
of α-antagonists (most used tamsulosin) 
and 9 studies of nifedipine, a calcium 
channel blocker.1 The studies were identi-
fi ed by a comprehensive search strategy 
that included Medline, EMBASE, and 
the Cochrane Controlled Trials Register 
from January 1980 to January 2007. The 
authors included all randomized trials or 
controlled clinical trials of medical thera-
py for adults with acute ureteral colic. 
The authors assessed the studies for 
quality using the Jadad scale, a validat-
ed scale of study quality. Higher scores 
represent better quality, including better 
documentation of randomization, blind-
ing, and follow-up. The authors specifi ed 
their planned sensitivity analyses, and 
used the random effects model to synthe-
size the results, which tends to provide a 
more conservative estimate of the effect. 
In other words, this was a very well 
done meta-analysis.
Twenty-two studies met the inclu-
sion criteria: 13 of α-antagonists, 6 of 
nifedipine, and 3 of both. In 13 of the 
16 studies of α-antagonists, tamsulosin 
(Flomax) was the study drug. The results 
from the terazosin (Hytrin) and doxazo-
sin (Cardura) studies were included with 
the tamsulosin studies. The Jadad quality 
scores of the 22 studies were fairly low, 
with a median of 2 (range of 0 to 3) on 
the 5-point scale. The most common de-
duction was because the study was not 
double-blinded.
❚  α-Antagonist studies
These 16 studies enrolled 1235 patients 
with distal ureteral stones. Mean stone 
size ranged from 4.3 to 7.8 mm. α-An-
tagonists improved the stone expulsion 
rate (RR= 1.59, 95% CI 1.44-1.75; 
NNT = 3.3). 
The mean time to expulsion of the 
stone ranged from 2.7 to 14.2 days and 
duration of therapy ranged from 1 to 7 
weeks. In the 9 trials that reported the 
time to stone expulsion, the stone came 
out between 2 and 6 days earlier than the 
control groups. 
Adverse effects were reported in 4% 
of patients receiving the active medica-
tion; most were mild. 
❚  Nifedipine studies
There were 686 patients in the 9 trials 
of nifedipine. The mean stone size was 
3.9 to 12.8 mm. Some studies included 
stones in the more proximal as well as 
the distal ureter. 
The stone passed 
2 to 6 days earlier 
with tamsulosin 
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Medical therapy 
makes sense
“Therapy using either α-antagonists or 
calcium channel blockers augments the stone 
expulsion rate compared to standard therapy 
for moderately sized distal ureteral stones.” 1  
CT showing 
distal ureteral stone
C O N T I N U E D
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A growing number
of physicians 
across specialties 
are using medical 
therapy in patients 
with ureteral 
stones
Nifedipine treatment increased the 
rate of stone expulsion (RR = 1.5, 95% CI 
1.34-1.68; NNT = 3.9). Time to stone ex-
pulsion was shorter in 7 of the 9 studies. 
Adverse effects were reported in 15% 
of the patients. Most of these were mild—
nausea, vomiting, asthenia, and dyspepsia. 
WHAT’S NEW
❚  Strong evidence for 
use of medical therapy 
The new fi ndings from the Singh meta-
analysis reviewed in this PURL supports 
physicians who have already adopted this 
practice and should encourage usage by 
those who have not yet done so.
❚  Inpatients in academic 
medical centers 
There is a growing trend to use tamsulo-
sin to facilitate passage of ureteral stones. 
The University Health System Consor-
tium (www.uhc.org) has complete clinical 
data on inpatients with ureteral stones, 
from 64 academic medical centers and 
teaching hospitals, between 2003 and 
2007. We used this database to analyze 
trends in the use of tamsulosin in 4300 
inpatients with ureteral stones (ICD 9 
code 5921). 
In 2003, only 3.3% of patients with 
a discharge diagnosis of ureteral stone 
received tamsulosin. In 2007, 34.1% of 
patients with ureteral stones discharged 
from these hospitals received tamsulo-
sin, with similar rates of use when strat-
ifi ed by the specialty of the attending 
physician at discharge (family medicine, 
emergency medicine, internal medicine, 
urology) (FIGURE 1). We noted a wide 
range in the rate of adoption of this 
practice among academic medical cen-
ters: 48% in the centers with the highest 
rate of usage and 4.4% in the centers 
with the lowest rate.
❚  Outpatients from a 
sample of US practices
The use of tamsulosin or nifedipine in 
outpatient practice was infrequent even 
2 or 3 years ago. We used the National 
Ambulatory Medical Care Survey data 
(www.cdc.gov/nchs/about/major/ahcd/
ahcd1.htm) from 2004 and 2005 (the 
most recent available), which provides 
a sample of all US outpatient practices. 
Only 7% of an estimated 1,345,000 
patients diagnosed with ureteral stones 
were prescribed either tamsulosin or 
nifedipine, and urologists cared for most 
of those.
These unpublished data show that 
physicians in academic medical centers 
are increasingly adopting the practice of 
using tamsulosin or nifedipine for expul-
sion of ureteral stones, that urologists ap-
pear to be the fi rst to begin using these 
medications in outpatients several years 
ago, and that this practice is being adopt-
ed actively in selected academic medical 
centers. 
 
CAVEATS
❚  Is either drug better? 
Too little data to tell 
Our conclusion is that the strengths of 
this meta-analysis outweigh the weak-
nesses, the fi ndings across studies are 
consistent, and the use of smooth-muscle 
relaxants for this indication makes sense 
from a mechanistic point of view.
The quality of a meta-analysis is 
only as good as the quality of the in-
cluded studies, and, in this case, the 
overall quality of studies was not uni-
Source: Unpublished data from the University Health System Consortium
% of inpatients in academic medical centers
who received tamsulosin for ureteral stones, 
by year
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Use drug therapy for ureteral stones
formly high. Median Jadad score, a 
summary measure of study quality, 
was 2, and the highest score was 3 (of 
a maximum of 5). The most common 
problem was lack of blinding, which 
can be critical in studies with subjec-
tive outcomes such as pain. We doubt 
that the lack of blinding led to any sig-
nifi cant misclassifi cation of outcome in 
this study, however. 
Patients either passed the stone or 
they didn’t, or had a surgical interven-
tion or not. It is reassuring that, when 
the best quality studies (Jadad score = 
3) were analyzed separately, the results 
were equally good. 
There have not been suffi cient head-
to-head trials to know if one is better 
than the other. We prefer α-antagonists 
because of the lower apparent side-effect 
profi le. Our analysis of the UHC data 
shows that most of the physicians who 
are using medical therapy are using tam-
sulosin primarily for this diagnosis. 
The majority of the patients in the 
studies included in the meta-analysis had 
been referred to a urologist. This raises 
the possibility that this treatment may 
not be as effective in patients with less 
severe symptoms for whom urological 
consultation is not necessary. 
CHALLENGES TO IMPLEMENTATION
❚  This change should be 
easy to put into practice
Tamsulosin is the best studied of the 
drugs, but also the most expensive. Based 
on the estimated number need to treat 
(NNT) of between 3 and 4 to prevent a 
surgical intervention and an estimated 
cost of around $90 for 1 month (www.
drugstore.com, February 16, 2008), tam-
sulosin seems like a good investment to 
avoid surgical intervention. 
The evidence for the other α-antago-
nists is consistent with that of tamsulosin, 
but there are fewer data, so it is not clear 
that the other agents will work as well.
Many people with renal colic are 
diagnosed and treated in the emergency 
department; they may not see their fam-
ily physician until some time after the 
stone is diagnosed. It is unclear what ef-
fect this delay might have on medication 
effectiveness.
Neither tamsulosin nor nifedipine 
have an FDA indication for ureterolithiasis. 
However, they are prescribed commonly, 
and most physicians are familiar with their 
use and adverse-effect profi les. ■
Acknowledgement
We acknowledge Sofi a Medvedev, PhD of the University 
HealthSystem Consortium (UHC) in Oak Brook, IL for 
analysis of the UHC Clinical Database and the National 
Ambulatory Medical Care Survey data.
References
 1.   Singh A, Alter HJ, Littlepage A. A systematic review 
of medical therapy to facilitate passage of ureteral 
calculi. Ann Emerg Med. 2007; 50:552-563.
 2.   Teichman JM. Clinical practice. Acute renal col-
ic from ureteral calculus. N Engl J Med. 2004; 
350:684-693.
 3.   Stamatelou KK, Francis ME, Jones CA, Nyberg LM, 
Curhan GC. Time trends in reported prevalence of 
kidney stones in the United States: 1976-1994. 
Kidney International. 2003; 63:1817-1823.
 4.   American Urological Association. Clinical Guidelines: 
Ureteral Calculi. Last updated 2007. Available at: 
http://www.auanet.org/guidelines/uretcal07.cfm. 
Accessed February 11, 2008.
 5.   Papa L, Stiell IG, Wells GA, Ball I, Battram E, Ma-
honey JE. Predicting intervention in renal colic pa-
tients after emergency department evaluation. Can 
J Emerg Med. 2005; 7:78-86.
 6.   Pearle MS, Calhoun EA, Curhan GC, Urologic Dis-
eases of America Project. Urologic diseases in 
America project: urolithiasis. J Urol. 2005; 173:848-
857.
 7.   Morse RM, Resnick MI. Ureteral calculi: natural his-
tory and treatment in an era of advanced technol-
ogy. J Urol. 1991; 145:263-265.
 8.   Peters HJ, Eckstein W. Possible pharmacological 
means of treating renal colic. Urol Res. 1975; 3:55-
59.
 9.   Borghi L, Meschi T, Amato F, Novarini A, Giannini A, 
Quarantelli C, et al. Nifedipine and methylpredniso-
lone in facilitating ureteral stone passage: a ran-
domized, double-blind, placebo-controlled study. 
J Urol. 1994; 152:1095-1098.
10.   Hollingsworth JM, Rogers MA, Kaufman SR, Brad-
ford TJ, Saint S, Wei JT, et al. Medical therapy to 
facilitate urinary stone passage: a meta-analysis. 
Lancet. 2006; 368:1171-1179.
Drugs used in the 
meta-analysis studies
α-Antagonists
Tamsulosin (Flomax)
Terazosin (Hytrin)
Doxazosin (Cardura)
Calcium channel blockers
Nifedipine (Adalat, Nifedical, Procardia)
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Tamsulosin is the 
best studied of the 
drugs, but also the 
most expensive
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